comprehensive -WSS

comprehensive

author：entertainment 2025-09-29 21:02:23 - browse：1

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Diagnostic tests are hitting their mathematical limits

WSS

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Boston Scientific acquires urology company Axonics for $3.7 billion

Fetal surgery at risk from Dobbs and new abortion restrictions

UnitedHealth’s Optum accused of antitrust violations in California

FDA early review: GLP

Will the market for weight loss drugs really reach $100 billion?

focus

comprehensive

focus

Anesthesiologist group: stop taking Ozempic before surgery

FDA early review: GLP

Psychedelics group wrestles with new pharma identity

Ascension's ugly legal battle over care for poor patients in Texas

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

At JPM 2024, hospital systems pitch financial strength to investors

23andMe had bad news about my health. I wish a person had delivered it

American taxpayers paid $1.8 trillion in health care costs in 2022

Affirmative action in medical school literally saved lives

Fetal surgery at risk from Dobbs and new abortion restrictions

hotspot

American taxpayers paid $1.8 trillion in health care costs in 2022

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

How to pay for weight loss drugs and save Medicare

UnitedHealth’s Optum accused of antitrust violations in California

Nonprofit, backed by Microsoft, to certify AI tools in health care

With clinical trial data readouts, here's how to spot spin

hotspot

focus

explore

entertainment